Comprehensive Analysis
Quick health check
Mobia Medical is not profitable right now, posting a steep net loss of -17.74M and an operating loss of -16.94M on 12.07M of revenue in its most recent quarter (Q1 2026). The company is burning real cash, with operating cash flow (CFO) running at -17.73M, meaning its accounting losses translate directly into money leaving the bank. Despite the heavy cash burn, the balance sheet is technically safe for the immediate future, boasting 55.73M in cash and short-term investments compared to 11.83M in current liabilities. However, there is clear near-term stress visible in the last two quarters: to survive its widening operating losses, the company had to suddenly issue 40.0M in long-term debt in Q1 2026, pushing its total long-term debt up from 7.13M at the end of 2025 to 40.73M.
Income statement strength
Revenue is moving in a phenomenal direction, climbing from 32.04M for the full fiscal year 2025 to 12.07M in Q1 2026 alone (a massive leap compared to 5.66M in Q1 2025). The gross margin is the absolute highlight of the income statement, sitting at a stellar 82.3% in Q1 2026, slightly up from 81.0% in FY 2025. Unfortunately, operating income is deteriorating, worsening from -10.3M in Q1 2025 to -16.94M in Q1 2026, primarily driven by massive Selling, General, and Administrative (SG&A) expenses. For investors, this creates a clear "so what": the company possesses exceptional pricing power and low manufacturing costs for its devices, but its cost control is virtually non-existent as it spends aggressively to chase that revenue growth.
Are earnings real?
Because the company is unprofitable, we must look at how closely its net losses match its actual cash burn. In Q1 2026, the company reported a net income of -17.74M and an operating cash flow (CFO) of -17.73M, showing a near 1:1 relationship. Free cash flow (FCF) is deeply negative at -17.77M. The balance sheet shows minor working capital movements explaining small cash drags: accounts receivable increased from 4.44M at the end of 2025 to 4.85M in Q1 2026, and inventory grew from 5.46M to 6.05M, meaning more cash was tied up on the shelves and in unpaid customer bills. Overall, the earnings (or rather, losses) are very "real," as there are no major accounting tricks hiding the fact that the day-to-day operations bleed cash.
Balance sheet resilience
Mobia's balance sheet currently falls into the "watchlist" category—it has high short-term liquidity but rapidly rising leverage. Looking at the latest quarter, liquidity is solid: total current assets of 71.71M easily eclipse total current liabilities of 11.83M, giving a very comfortable current ratio. However, leverage is a growing concern. Total long-term debt skyrocketed to 40.73M in Q1 2026 from just 7.13M three months prior. While the company's cash pile of 55.73M technically means net debt is still negative (they have more cash than debt), the solvency comfort is precarious. The company cannot service its debt using CFO, which is severely negative, meaning it relies entirely on its shrinking cash reserves to pay the 0.36M in quarterly interest expenses. If debt continues rising while cash flow remains this weak, the balance sheet will become highly risky.
Cash flow “engine”
The company’s cash flow engine is running in reverse, forcing it to fund operations entirely through external financing. The CFO trend is negative and worsening, dropping from -9.72M in Q1 2025 to -17.73M in Q1 2026. Interestingly, capital expenditures (Capex) are almost non-existent at just -0.04M in the recent quarter, implying the company likely outsources its manufacturing or runs a highly asset-light device model. Because FCF is deeply negative, cash is not being used for shareholder returns or debt paydown; rather, the company relies heavily on financing cash flows—like the 40.0M in newly issued debt in Q1 2026 and 64.71M in preferred stock issued in 2025—just to build its cash reserves and survive. Consequently, the cash generation is completely uneven and organically unsustainable.
Shareholder payouts & capital allocation
Mobia Medical does not currently pay a dividend, which is the correct choice given the severe lack of free cash flow. Looking at share count changes, the company has heavily diluted its equity base recently. The latest annual report shows a shares change of 47.71% and a buyback yield dilution of -12.54%, meaning management is issuing new shares (often preferred stock, as seen in the 64.71M issuance in 2025) to raise capital. For investors today, this rising share count dilutes ownership, meaning the underlying business has to grow significantly faster just to keep the per-share value flat. Right now, cash is going directly into funding massive operating losses, and the shift from equity financing in 2025 to debt financing in 2026 is stretching leverage in a way that risks long-term shareholder value if profitability isn't achieved soon.
Key red flags + key strengths
The company has two major strengths: 1) Revenue growth is explosive, up over 104% year-over-year in FY 2025 and continuing into 2026. 2) Gross margins are superb at 82.3%, proving the underlying product is highly lucrative to produce. However, there are severe red flags: 1) The cash burn is alarming, with -17.73M in CFO lost in a single quarter. 2) SG&A expenses are completely oversized, consuming 208% of total revenue in Q1 2026. 3) The sudden addition of 40.0M in debt signals a heavy reliance on continuous capital injections. Overall, the foundation looks risky because while the product clearly has market fit and high margins, the business model is currently far too expensive to run and entirely reliant on outside funding to survive.